share_log

Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7

Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7

Truist Securities维持对Sangamo Therapeutics的买入,将目标股价下
Benzinga ·  2023/08/15 10:37

Truist Securities analyst Nicole Germino maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and lowers the price target from $8 to $7.

Truist Securities分析师妮可·杰尔米诺维持Sangamo Therapeutics(纳斯达克股票代码:SGMO)的买入,并将目标股价从8美元下调至7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发